ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis

A Mathematical Theory of Evidence

Shafer, G. R. (2020) · Princeton University Press eBooks · doi:10.2307/j.ctv10vm1qb · Cited by 11,786 · see citing works

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works

A method of comparing the areas under receiver operating characteristic curves derived from the same cases

Hanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016 · see citing works

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 3× · see citing works

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works

A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C

Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406 · see citing works

The NAFLD fibrosis score

Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,198 · see citing works

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · see citing works

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106 · see citing works

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.06038.x · Cited by 2,078 · see citing works

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875 · see citing works

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis

Angulo, P., Keach, J. C., Batts, K., & Lindor, K. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,708 · see citing works

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Shah, A. G., Lydecker, A. D., Murray, K. F., Tetri, B., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,561 · see citing works

Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans

Huffman, J. E., Albrecht, E., Teumer, A., Mangino, M., Kapur, K., Johnson, T., Kutalik, Z., Pirastu, N., Pistis, G., Lopez, L. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119752 · Cited by 1,226 · see citing works

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

Mofrad, P., Contos, M., Haque, M., Sargeant, C. C., Fisher, R., Luketic, V., Sterling, R., Shiffman, M., Stravitz, R., & Sanyal, A. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,221 · see citing works

Pitfalls of Liver Stiffness Measurement: A 5-Year Prospective Study of 13,369 Examinations

Castéra, L., Foucher, J., Bernard, P., Carvalho, F., Allaix, D., Merrouche, W., Couzigou, P., & de Lédinghen, V. (2009) · Hepatology · doi:10.1002/hep.23425 · Cited by 1,157 · see citing works

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

Forns, X., Ampurdanés, S., Llovet, J. M., Aponte, J. Á. N., Quintó, L., Martínez‐Bauer, E., Bruguera, M., Sánchez-Tapias, J. M., & Rodés, J. (2002) · Hepatology · doi:10.1053/jhep.2002.36128 · Cited by 1,123 · see citing works

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067 · see citing works

Liver fibrosis in overweight patients

Ratziu, V., Giral, P., Charlotte, F., Bruckert, É., Thibault, V., Theodorou, I. D., Khalil, L., Turpin, G., Opolon, P., & Poynard, T. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70364-7 · Cited by 969 · see citing works

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease

McPherson, S., Stewart, S. F., Henderson, E., Burt, A. D., & Day, C. P. (2010) · Gut · doi:10.1136/gut.2010.216077 · Cited by 946 · see citing works

Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis

McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.453 · Cited by 945 · see citing works

Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality

Younossi, Z. M., Stepanova, M., Rafiq, N., Makhlouf, H. R., Younoszai, Z., Agrawal, R., & Goodman, Z. D. (2011) · Hepatology · doi:10.1002/hep.24268 · Cited by 636 · see citing works

Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis

Leeflang, M., Bossuyt, P. M., & Irwig, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.04.007 · Cited by 485 · see citing works

Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

Younossi, Z. M., Gramlich, T., Liu, Y. C., Matteoni, C. A., Petrelli, M., Goldblum, J. R., Rybicki, L. A., & McCullough, A. J. (1998) · PubMed · Cited by 321 · see citing works

Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis

Dowman, J. K., Tomlinson, J., & Newsome, P. N. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312 · see citing works

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Poynard, T., Halfon, P., Castéra, L., Munteanu, M., Imbert‐Bismut, F., Ratziu, V., Benhamou, Y., Bourlière, M., de Lédinghen, V., & FibroPaca Group (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.085795 · Cited by 237 · see citing works

The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.

(2013) · Europe PMC (PubMed Central) · Cited by 214 · see citing works

Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease

Adams, L. A., George, J., Bugianesi, E., Rossi, E., de Boer, W. B., van der Poorten, D., Ching, H. L., Bulsara, M. K., & Jeffrey, G. P. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06774.x · Cited by 172 · see citing works

Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R. K., Goodman, Z. D., Schuppan, D., & Patel, K. (2014) · Liver International · doi:10.1111/liv.12700 · Cited by 144 · see citing works

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease

Petta, S., Vanni, E., Bugianesi, E., Marco, V. D., Cammà, C., Cabibi, D., Mezzabotta, L., & Craxı̀, A. (2014) · Liver International · doi:10.1111/liv.12584 · Cited by 137 · see citing works

How to Measure the Diagnostic Accuracy of Noninvasive Liver Fibrosis Indices: The Area Under the ROC Curve Revisited

Lambert, J., Halfon, P., Pénaranda, G., Bédossa, P., Cacoub, P., & Carrat, F. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097923 · Cited by 137 · see citing works

Estimating and Comparing Diagnostic Tests’ Accuracy When the Gold Standard Is Not Binary1

Obuchowski, N. A. (2005) · Academic Radiology · doi:10.1016/j.acra.2005.05.013 · Cited by 122 · see citing works

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

Tanwar, S., Trembling, P. M., Guha, I. N., Parkes, J., Kaye, P., Burt, A. D., Ryder, S. D., Aithal, G. P., Day, C. P., & Rosenberg, W. M. (2012) · Hepatology · doi:10.1002/hep.26030 · Cited by 114 · see citing works

The macrophage activation marker sCD 163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease

Kazankov, K., Francisco Barrera, M., Møller, H. J., Rosso, C., Bugianesi, E., David, E., Jouness, R. I. K., Esmaili, S., Eslam, M., McLeod, D. J., et al. (2016) · Liver International · doi:10.1111/liv.13150 · Cited by 113 · see citing works

Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology

Gawrieh, S., Knoedler, D. M., Saeian, K., Wallace, J. R., & KOMOROWSKI, R. A. (2010) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2010.08.001 · Cited by 102 · see citing works

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis European Association for the Study of the Liver ⇑ , Asociación Latinoamericana para el Estudio del Hígado

Castéra, L., Chan, H. L., Chan, Y., Arrese, M. A., & Han, K. (2015) · Cited by 83 · see citing works

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy

Karsdal, M. A., Henriksen, K., Nielsen, M. J., Byrjalsen, I., Leeming, D. J., Gardner, S. D., Goodman, Z. D., Patel, K., Krag, A. A., Christiansen, C., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00283.2016 · Cited by 81 · see citing works

FibroGENE: A gene-based model for staging liver fibrosis

Eslam, M., Hashem, A. M., Romero‐Gómez, M., Berg, T., Dore, G. J., Mangia, A., Chan, H. L., Irving, W. L., Sheridan, D. A., Abate, M. L., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.008 · Cited by 75 · see citing works

Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis

Toshio, F., Fukushima, J., Shiga, J., Takahashi, Y., NAKANO, T., Maeyama, S., Masayuki, U., Ohbu, M., Matsumoto, T., & Matsumoto, K. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.09.018 · Cited by 74 · see citing works

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients

Nielsen, M. J., Kazankov, K., Leeming, D. J., Karsdal, M. A., Krag, A. A., Francisco Barrera, M., McLeod, D. J., George, J., & Grønbæk, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137302 · Cited by 67 · see citing works

Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management

Armstrong, M. J., Hazlehurst, J., Parker, R., Koushiappi, E., Mann, J. P., Khan, S., Philips, A., Chandler, L., Johnson, J. L., Round, M., et al. (2013) · QJM · doi:10.1093/qjmed/hct198 · Cited by 53 · see citing works

Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis

Mahady, S. E., Macaskill, P., Craig, J. C., Wong, G. L., Chu, C. W., Chan, H. L., George, J., & Wong, V. W. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.02.031 · Cited by 52 · see citing works

Suboptimal performance of simple noninvasive tests for advanced fibrosis in C hinese patients with nonalcoholic fatty liver disease

Xun, Y., Fan, J., Zang, G. Q., Liu, H., Jiang, Y., Xiang, J., Huang, Q., & Shi, J. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2012.00631.x · Cited by 42 · see citing works

Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury

Nielsen, M. J., Karsdal, M. A., Kazankov, K., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13819 · Cited by 39 · see citing works

NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks

Harrison, S. A., Rossi, S., Bashir, M. R., Guy, C., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., Ling, L., & DePaoli, A. M. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30352-0 · Cited by 12 · see citing works

Non-alcoholic fatty liver disease

Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease

Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494 · see citing works

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · see citing works

Impact of non-invasive biomarkers on hepatology practice: past, present and future

Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224 · see citing works

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00017-1 · Cited by 224 · see citing works

Collagen biology and non‐invasive biomarkers of liver fibrosis

Karsdal, M. A., Daniels, S. J., Holm Nielsen, S., Bager, C., Rasmussen, D. G. K., Loomba, R., Surabattula, R., Villesen, I. F., Luo, Y., Shevell, D., et al. (2020) · Liver International · doi:10.1111/liv.14390 · Cited by 197 · see citing works

Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis

Andersson, A., Kelly, M., Imajo, K., Nakajima, A., Fallowfield, J. A., Hirschfield, G., Pavlides, M., Sanyal, A. J., Noureddin, M., Banerjee, R., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.041 · Cited by 148 · see citing works

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease

Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140 · see citing works

ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD

Corey, K. E., Pitts, R., Lai, M., Loureiro, J., Masia, R., Osganian, S. A., Gustafson, J. L., Hutter, M. M., Gee, D. W., Meireles, O. R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.026 · Cited by 88 · see citing works

A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients

Eslam, M., Wong, G. L.-H., Hashem, A. M., Chan, H. L.-Y., Nielsen, M. J., Leeming, D. J., Chan, A. W.-H., Chen, Y., Duffin, K. L., Karsdal, M., et al. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001059 · Cited by 53 · see citing works

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes

Bril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019) · Diabetes Care · doi:10.2337/dc18-2578 · Cited by 52 · see citing works

Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date

Albhaisi, S., & Sanyal, A. J. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00305-z · Cited by 27 · see citing works

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia